Supplementary Material for: Pembrolizumab Plus Lenvatinib for Postoperative Recurrent TFEB

A 2026 case report from figshare details the treatment of a 67-year-old male patient with postoperative recurrent TFEB-amplified renal cell carcinoma. The report describes the diagnostic challenges, genomic profiling results, and the patient's response to combination therapy with pembrolizumab and lenvatinib. The author is listed as figshare admin karger, and the material is licensed under CC-BY-4.0.

Use Cases

• Reviewing a clinical case for educational purposes based on the detailed patient history and treatment timeline.
• Analyzing the molecular diagnostic pathway for TFEB-amplified RCC based on the description of FISH and genomic profiling.
• Studying treatment response patterns in rare cancers based on the reported partial and complete response to pembrolizumab plus lenvatinib.

Strengths

• Includes specific clinical details such as patient age (67), diagnosis timeline, and treatment response metrics.
• Provides molecular diagnostic confirmation via FISH and comprehensive genomic profiling, as described.
• Document is licensed under CC-BY-4.0, permitting open sharing and adaptation.

Limitations

• The dataset is a single case report (116.1 KB DOCX file), representing an extremely limited sample size of n=1.
• Row count and column-level documentation are absent; data structure and variables must be inferred from the narrative text.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely a clinical case report authored by medical professionals.

Time Range

Case timeline spans from patient presentation through at least one year of follow-up treatment.

Freshness

Last updated 2026-06-03 05:55:25.